| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN7 |
| Uniprot No | O95471 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-211aa |
| 氨基酸序列 | MANSGLQLLGFSMALLGWVGLVACTAIPQWQMSSYAGDNIITAQAMYKGLWMDCVTQSTG MMSCKMYDSVLALSAALQATRALMVVSLVLGFLAMFVATMGMKCTRCGGDDKVKKARIAM GGGIIFIVAGLAALVACSWYGHQIVTDFYNPLIPTNIKYEFGPAIFIGWAGSALVILGGA LLSCSCPGNESKAGYRVPRSYPKSNSSKEYV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLDN7重组蛋白的3篇参考文献及简要摘要：
---
1. **文献名称**: *"Claudin-7 modulates cell polarity and metastasis in colorectal cancer through β-catenin/Snai1 signaling"*
**作者**: Li J, et al.
**摘要**: 本研究利用重组CLDN7蛋白体外处理结肠癌细胞，发现其通过调控β-catenin/Snai1信号通路抑制上皮-间质转化(EMT)，从而降低癌细胞迁移和转移能力，揭示了CLDN7在肿瘤转移中的潜在抑制作用。
---
2. **文献名称**: *"Recombinant Claudin-7 protein enhances tight junction barrier function in human keratinocytes"*
**作者**: Suzuki H, et al.
**摘要**: 通过在大肠杆菌中表达并纯化重组CLDN7蛋白，研究发现其能显著增强人角质细胞紧密连接的屏障功能，为治疗皮肤屏障相关疾病(如特应性皮炎)提供了实验依据。
---
3. **文献名称**: *"Structural insights into claudin-7 self-assembly and interaction with hepatitis C virus core protein"*
**作者**: Zhang Y, et al.
**摘要**: 该研究通过重组CLDN7蛋白的晶体结构分析，揭示了其四聚体自组装机制，并发现CLDN7与丙型肝炎病毒核心蛋白直接结合，可能参与病毒入侵宿主细胞的分子过程。
---
**备注**：上述文献信息为示例性质，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
Claudin-7 (CLDN7) is a key component of tight junctions, specialized protein complexes that regulate paracellular permeability and maintain cell polarity in epithelial and endothelial tissues. As a member of the claudin family, it consists of four transmembrane domains, two extracellular loops, and intracellular N- and C-termini. CLDN7 is predominantly expressed in epithelial-rich tissues such as the intestine, kidney, and skin, where it contributes to barrier formation and ion selectivity. Dysregulation of CLDN7 has been linked to pathological conditions, including cancer, inflammatory bowel disease, and skin disorders. In cancer, its role appears context-dependent: downregulation in colorectal cancer correlates with enhanced metastasis, while overexpression in certain carcinomas may promote drug resistance.
Recombinant CLDN7 protein is engineered using recombinant DNA technology, typically expressed in systems like E. coli or mammalian cells to ensure proper post-translational modifications. The purified protein retains structural and functional integrity, enabling studies on tight junction dynamics, disease mechanisms, and therapeutic targeting. Researchers utilize it to investigate CLDN7's interactions with other tight junction proteins (e.g., occludin, ZO-1) or pathogens targeting epithelial barriers. It also serves as an antigen for antibody development or a standard in diagnostic assays. Quality control involves SDS-PAGE, Western blotting, and mass spectrometry to verify purity, molecular weight (~22-25 kDa), and epitope availability. Current challenges include maintaining protein stability due to its hydrophobic transmembrane regions and replicating native membrane environments in vitro. Ongoing research focuses on its dual role in tumor suppression/progression and potential as a biomarker or target for epithelial barrier-related therapies.
×
